Company intelligence / Profile preview
Manzanita Pharmaceuticals
Woodside, California, United Statesmanzanitapharmaceuticals.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Manzanita Pharmaceuticals has developed a proprietary platform that attaches near-infrared dyes or drugs to recombinant human neurotrophins such as NGF and BDNF. Their lead product, NerveLight, is an intra-operative nerve imaging agent designed to help surgeons visualize nerves during procedures like radical prostatectomy, aiming to reduce complications such as impotence or incontinence. The company also develops non-opiate glucocorticoid injectables for chronic pain. At least one pipeline program targeting optic neuritis with FA-rhBDNF is in preclinical development.[1][3][4][8]
- Therapeutic areas
- OncologyNeurology
- Modalities
- Small molecules (dyes/drugs conjugated to recombinant human proteins)[1]Modified glucocorticoids[3][4]
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Manzanita Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Manzanita Pharmaceuticals.